How Brady Beat Cancer with Better TreatmentThree years after 14-year-old Brady learned he had cancer, he and his parents reflect on their family’s journey and the opportunity to join the Children’s Oncology Group’s effort to bring less toxic treatments to patients. This is Brady’s larotrectinib story.
|
On the horizon — A future with minimal chemotherapy for babies with soft tissue tumorsFirst, Dr. Ted Laetsch proved that larotrectinib shrank tumors in kids who'd been treated with chemotherapy. His latest study showed larotrectinib could do the same — even without chemo.
|
How One COG Researcher is Working to Prevent Heart Failure in Childhood Cancer SurvivorsIt’s an alarming statistic: Pediatric cancer patients are five times more likely to develop heart failure compared to their peers. Thankfully, Dr. Saro Armenian's ground-breaking research is proving that risk can be significantly lowered.
|
COG research leads to game-changing improvements for pediatric Hodgkin lymphoma treatmentWhen scientists tested a new, more targeted treatment for pediatric Hodgkin lymphoma, they hoped it might work as well as the standard treatments. The results revealed something they never expected.
|
Dr. Brenda Weigel is on the front lines of developing new drugs for pediatric cancer. We caught up with her to learn about the latest developments in precision medicine — and how philanthropy makes a difference in her work.
|
An immunotherapy with game-changing – life-saving – potential for patients with relapsed B-cell ALLA new immunotherapy is providing another path to remission for relapsed B-cell ALL. Dr. Laura Hogan shares news of a long-awaited breakthrough for patients with the same pediatric cancer she had.
|
The Children’s Oncology Group Foundation newsletter is made possible by The Andrew McDonough B+ Foundation and Message Lab Media.
We hope that sharing stories about COG research breakthroughs, improved care, patient families and generous donors will strengthen and inspire
the pediatric cancer community. |